New brand drug - Voranigo (vorasidenib)

Voranigo (vorasidenib) - indicated for 1) grade 2 IDH1- or IDH2-positive astrocytoma in adult and pediatric patients 12 years and older and 2) grade 2 IDH1- or IDH2-positive oligodendroglioma in adult and pediatric patients 12 years and older.